The results indicate that cathepsin O protected BPH, cathepsin X posed a risk for prostatitis, and prostatitis had a negative impact on cathepsin V. The findings provide valuable insights into the role of cathepsins in developing BPDs, potentially influencing the development of diagnostic and therapeutic strategies for cathepsins in patients with BPDs. This evidence concerns the gene CTSS and benign prostatic hyperplasia.